Small nucleic acids gain momentum: leading companies go public in the capital market, domestic supply chains benefit, and capital expenditure accelerates

2026-02-20 02:05:46

Innovation is the eternal main theme, and small nucleic acids are expected to become a new highlight in the pharmaceutical industry by 2026.

Rebio Biotech completed its Hong Kong IPO, raising 1.594 billion HKD, and has continued to rise after listing, potentially becoming a new highlight in the pharmaceutical sector.

What is the industry logic behind small nucleic acids?

Which links in the domestic supply chain benefit?

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes